Indacaterol/glycopyrrolate Significantly Improves COPD Assessment Test (cat) Scores In Us Patients With Moderate-To-Severe COPD: Subgroup Analysis From Pooled Flight1 And Flight2 Studies

被引：0
|
作者：
Fogel, R. [1 ]
Maitra, S. [2 ]
Patalano, F. [3 ]
Banerji, D. [1 ]
机构：
[1] Novartis Pharmaceut, E Hanover, NJ USA
[2] Novartis Healthcare Pvt Ltd, Hyderabad, Andhra Pradesh, India
[3] Novartis Pharma AG, Basel, Switzerland
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2016年 / 193卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A6801
引用
收藏
页数：1
相关论文
共 46 条
  • [21] QVA149, Twice Daily, Is Well Tolerated in Patients With Moderate-to-Severe COPD and Has a Safety Profile Similar to Placebo: FLIGHT1 and FLIGHT2 Pooled Analysis in the Subgroup of Patients From the USA
    Ayers, Tim
    Fogel, Robert
    Banerji, Donald
    Maitra, Samopriyo
    Schubert-Tennigkeit, Agnes Annette
    CHEST, 2015, 148 (04)
  • [22] Indacaterol/glycopyrrolate Improves Lung Function, Dyspnea And Health Status In Symptomatic Patients With COPD Using Prior Lama, Laba Or Laba/ics: Post-Hoc Analysis From Pooled Flight1 And Flight2 Studies
    Ayers, T.
    Maitra, S.
    Fogel, R.
    Banerji, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [23] Long-Term Safety And Tolerability Of Indacaterol/glycopyrrolate In Moderate-To-Severe COPD Patients From The Us: A Subgroup Analysis From The Flight3 Study
    Ferguson, G. T.
    Schubert-Tennigkeit, A. A.
    Thach, C.
    Banerji, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [24] Safety Of Indacaterol/glycopyrrolate 27.5/15.6 μg Twice Daily In Patients With Moderate-To-Severe COPD: Analysis From The Flight Studies
    Ferguson, G. T.
    Donohue, J. F.
    Fucile, S.
    Yadao, A.
    Maitra, S.
    Ayers, T.
    Fogel, R.
    Patalano, F.
    Banerji, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [25] Efficacy And Safety Of Indacaterol/glycopyrrolate In The Us Versus Non-Us Population: Comparison Of Clinical Data From A Pooled Analysis Of Flight1 And Flight2
    Banerji, D.
    FowlerTaylor, A.
    Thach, C.
    Patalano, F.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [26] Lung Function and Patient-Reported Outcomes Response to Indacaterol/Glycopyrrolate (UTIBRON™ Neohaler®) in Chronic Obstructive Pulmonary Disease (COPD) Patients by Reversibility: Pooled Analysis of the FLIGHT1 and FLIGHT2 Studies
    Sharma, S.
    Goodin, T.
    Bowling, A.
    Price, B.
    Ozol-Godfrey, A.
    Sanjar, S.
    Ohar, J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [27] Lung Function and Patient-Reported Outcomes Response to Indacaterol/Glycopyrrolate (UTIBRON™ Neohaler®) in Chronic Obstructive Pulmonary Disease (COPD) Patients by Smoking Status: Pooled Analysis of the FLIGHT1 and FLIGHT2 Studies
    Sanjar, S.
    Goodin, T.
    Bowling, A.
    Price, B.
    Ozol-Godfrey, A.
    Sharma, S.
    Tashkin, D. P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [28] Long-Term Maintenance Bronchodilation With Indacaterol/Glycopyrrolate Versus Indacaterol in Moderate-to-Severe COPD Patients: The FLIGHT 3 Study
    Ferguson, Gary T.
    Taylor, Angel Fowler
    Thach, Chau
    Wang, Qian
    Schubert-Tennigkeit, Agnes A.
    Patalano, Francesco
    Banerji, Donald
    CHRONIC OBSTRUCTIVE PULMONARY DISEASES-JOURNAL OF THE COPD FOUNDATION, 2016, 3 (04): : 716 - 728
  • [29] Improvement in Lung Function, Dyspnea, and Health Status With QVA149 Compared With Placebo in the Subgroup of Patients With COPD From the USA: FLIGHT1 and FLIGHT2 Pooled Analysis
    FowlerTaylor, Angel
    Fogel, Robert
    Banerji, Donald
    Maitra, Samopriyo
    CHEST, 2015, 148 (04)
  • [30] Analysis of Improvement in SGRQ Component Scores With QVA149: Pooled Data From the FLIGHT1 and FLIGHT2 Studies
    Jones, Paul
    Larbig, Michael
    Maitra, Samopriyo
    FowlerTaylor, Angel
    Banerji, Donald
    CHEST, 2015, 148 (04)
12345